Is Keytruda Approved for Lung Cancer?
Yes, Keytruda (pembrolizumab) is FDA-approved for several types of non-small cell lung cancer (NSCLC), the most common lung cancer form. Approvals cover first-line treatment combined with chemotherapy for metastatic NSCLC without EGFR or ALK mutations, as well as monotherapy for tumors with high PD-L1 expression (TPS ≥50%) and no EGFR/ALK alterations. It's also approved for NSCLC after platinum chemotherapy progression.[1]
How Is Keytruda Used in Lung Cancer Treatment?
Keytruda, a PD-1 inhibitor immunotherapy, blocks cancer cells from evading immune detection. In NSCLC, it's given intravenously every 3 or 6 weeks at 200 mg or 400 mg doses. Regimens include:
- Keytruda + pemetrexed + platinum chemo for nonsquamous NSCLC.
- Keytruda + carboplatin + paclitaxel or nab-paclitaxel for squamous NSCLC.
Treatment continues up to 2 years or until disease progression/toxicity.[1][2]
What Do Clinical Trials Show for Effectiveness?
KEYNOTE-024 trial showed Keytruda monotherapy extended overall survival to 30 months vs. 14.2 months with chemotherapy in PD-L1-high NSCLC (HR 0.60).[3] KEYNOTE-189 (chemo combo) improved survival to 22 months vs. 10.6 months (HR 0.49).[4] KEYNOTE-407 (squamous) reported 17.1 months vs. 11.6 months (HR 0.64).[5] Response rates range 45-50% in PD-L1-high cases.
What About Small Cell Lung Cancer?
Keytruda lacks full FDA approval for small cell lung cancer (SCLC), which is rarer and more aggressive. KEYNOTE-604 trial showed modest progression-free survival benefit (2.1 months vs. 1.4 months) with chemo combo but missed overall survival endpoint, so it's not standard.[6]
Common Side Effects and Patient Risks
Fatigue, musculoskeletal pain, rash, diarrhea, and decreased appetite occur in >20% of patients. Serious immune-related effects include pneumonitis (3-5%), colitis, hepatitis, and endocrinopathies. Lung cancer patients face higher pneumonitis risk; monitoring with imaging is standard.[1][2]
Who Qualifies for Keytruda in Lung Cancer?
Eligibility requires PD-L1 testing (via IHC 22C3 assay) and confirmed NSCLC without targetable mutations. It's not for small cell, EGFR/ALK-positive, or ROS1-positive NSCLC as first-line unless post-progression.[1] Oncologists use NCCN guidelines for patient selection.
How Does Keytruda Compare to Other Lung Cancer Drugs?
Vs. chemotherapy alone: Doubles response duration and survival in PD-L1-high NSCLC.[3] Vs. Opdivo (nivolumab): Similar PD-1 class, but Keytruda has broader first-line approvals and better chemo combo data.[7] Vs. Tagrisso (osimertinib): Reserved for EGFR-mutant NSCLC; Keytruda follows if progression occurs.[8]
Cost and Access for Lung Cancer Patients
A 3-week cycle costs ~$11,500 (U.S. list price), often covered by insurance/Medicare with prior authorization. Patient assistance via Merck covers copays for eligible uninsured/underinsured.[9]
When Does Keytruda's Patent Expire?
Keytruda's core composition patent (U.S. 8,354,509) expires in 2028, with formulation patents to 2030+ amid ongoing litigation. Biosimilars unlikely before 2028; Merck sues challengers.[10]DrugPatentWatch.com
[1]: FDA Label - Keytruda (updated 2024). Link
[2]: NCCN Guidelines - NSCLC (v.5.2024). Link
[3]: NEJM - KEYNOTE-024 (2016). Link
[4]: NEJM - KEYNOTE-189 (2018). Link
[5]: NEJM - KEYNOTE-407 (2018). Link
[6]: Lancet - KEYNOTE-604 (2020). Link
[7]: CheckMate-227 vs. KEYNOTE-189 meta-analyses (2023).
[8]: FDA Label - Tagrisso.
[9]: Merck Access Program (2024). Link
[10]: DrugPatentWatch - Keytruda Patents. Link